Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patien…
Biotechnology
US, Ponte Vedra [HQ]
Lobbying Analysis
Lobbying · US Senate · Influence
Cadrenal Therapeutics, Inc. Common Stock has no lobbying expenses in our database.
History
Download| FY | Quarter | Expense For Lobby Disclosure | LDA Reference |
|---|---|---|---|
| No data |